Lercanidipine Sandoz

Lercanidipine, the active ingredient in Lercanidipine Sandoz, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension by relaxing vascular smooth muscle and helping achieve sustained blood pressure control.

GNH USA supplies Lercanidipine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Lercanidipine is an antihypertensive agent that acts on the vascular smooth muscle to lower blood pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: improves systolic pressure control in older patients. - General high blood pressure: provides consistent blood pressure reduction as part of long‑term therapy.

Lercanidipine may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate in some patients. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lercanidipine, several safety considerations should be observed.

- Blood pressure monitoring: regularly assess to ensure adequate control and avoid excessive lowering. - Discontinuation: avoid abrupt cessation; taper under medical guidance to prevent rebound hypertension. - Hepatic impairment: use with caution in patients with liver dysfunction, as metabolism may be affected. - Elderly patients: start at lower doses and monitor for increased sensitivity to hypotensive effects. - CYP3A4 inhibitors: avoid concomitant strong inhibitors without dose adjustment. - Store below 25°C: keep in the original pack, protect from moisture.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of adverse effects. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Grapefruit juice: can elevate drug levels and precipitate hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood pressure‑lowering effect, may require dose adjustment. - Diuretics: enhanced antihypertensive response, monitor electrolytes. - ACE inhibitors or ARBs: combined therapy may increase risk of hypotension and renal impairment.